Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix – for discoloured and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix in Australia and New Zealand.
“The agreement is part of our international commercialization of Emtrix, which now will be marketed in another large market. We currently have secured distributors for Emtrix in over 20 markets,” comments Moberg Derma's CEO, Peter Wolpert.
Emtrix is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix was initiated in the first markets in September 2010. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 8 June, 08:00 a m.
Moberg Derma AB (publ.), develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery.